Immutrin
Next Generation Antibody Therapy for Reversal of Amyloidosis
United Kingdom · $87.0M raised
- Business Model
- B2B
- Website
- immutrin.com
- Total Funding
- $87.0M
- Last Round
- $87.0M Venture RoundMar 2026
- Rounds
- 1
About
Immutrin is a UK-based biotechnology company developing next-generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis. Its lead asset targets ATTR cardiomyopathy with a unique mechanism designed to selectively remove established amyloid fibrils. The company was co-founded by Cambridge Innovation Capital alongside Nobel Laureate Sir Gregory Winter FRS and Professor Sir Mark Pepys FRS.
Summary
Immutrin is a Biotech company based in United Kingdom. It has raised $87.0M in total across 1 round, most recently a $87.0M Venture Round round in Mar 2026. Investors include Frazier Life Sciences, F-Prime Capital and Qiming VP.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2026
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company